AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01355679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Therapy
Description: A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
Study NCT02965794 — intervention group
Intervention type: OTHER
Intervention: Care pathways for colorectal cancer
Description: development of a care pathway for this patient group
Study NCT02728648 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Pain Management
Study NCT02250079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylene plastic bag
Description: Inborn neonates with both a gestational age >29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
Study NCT02250079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
Study NCT03773536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine given with single low dose primaquine
Description: Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
Study NCT00884962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric Lung Volume Reduction System (PLVR)
Description: 20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
Study NCT01584791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel napadisilate + aspirin
Description: clopidogrel napadisilate 75mg + aspirin 100mg
Study NCT01584791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel bisulfate + aspirin
Description: clopidogrel bisulfate 75mg + aspirin 100mg
Study NCT00904670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quillivant Oral Suspension XR
Description: Oral Suspension 25mg/5mL; 20-60 mg/day
Study NCT00904670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
Study NCT00904670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
Study NCT00271856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: 8 week MBSR course
Study NCT00271856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-education and self-management workshop
Description: 8-week group covering a variety of educational topics about managing HIV infection.
Study NCT00323960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
Study NCT00323960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN + CSA
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
Study NCT00323960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN + MTX
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
Study NCT01599312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Forces exerted on teeth during intubation
Description: Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
Study NCT03319459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
Study NCT03319459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor inhibitor antineoplastic agent
Study NCT03319459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2/neu receptor inhibitor
Study NCT03456349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: HTL0018318
Study NCT03456349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00435227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
Study NCT00435227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
Study NCT05268692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS
Description: drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
Study NCT05268692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnP
Description: drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
Study NCT00261378 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DC Bead with Doxorubicin
Study NCT04249791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of the uterus from live donor.
Description: Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
Study NCT01432665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study NCT01432665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study NCT01432665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study NCT02044367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Pellets (multiple dose of dabigatran)
Study NCT02044367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Granules resolved in reconstitution solution (multiple dose of dabigatran)
Study NCT02044367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Hard capsule (multiple dose of dabigatran)
Study NCT01852500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study NCT04384653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)
Study NCT04384653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
Study NCT04384653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medfusion 3500 (v6) precision infusion pump
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)
Study NCT01108003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: Given orally
Study NCT01108003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01108003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mango Juice
Description: given orally
Study NCT05047458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).
Study NCT05047458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.
Study NCT00268723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol tartrate HFA MDI
Description: levalbuterol MDI 90 mcg QID
Study NCT00268723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study NCT03812874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-9908 Injection
Description: Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II).
Study NCT03812874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTX-9908 Injection
Description: Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II).
Study NCT03812874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)
Study NCT02250937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT02250937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02250937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT02250937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02250937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02250937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT02250937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02250937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01872494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local
Description: This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
Study NCT01872494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous
Description: This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
Study NCT01872494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.33% ropivacaine 250ml
Study NCT01872494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
Study NCT01902914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hearing Aids Evaluation
Description: Functional Gain Sound field Speech Audiometry
Study NCT01902914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aids Evaluation
Description: Functional Gain Sound field Speech Audiometry
Study NCT04357158 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AeonoseTM
Description: All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with >2 weeks in between).
Study NCT01086163 — intervention group
Intervention type: DRUG
Intervention: Omacor, omega-3 fatty acids in CAD patients
Description: Omacor 1g versus 2g daily versus placebo
Study NCT03363529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic light
Description: Dynamic lighting is light that changes in intensity and spectral distribution during the day
Study NCT03363529 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Standard lighting is non-dynamical light corresponding to standard hospital lighting.
Study NCT02746926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study NCT03595969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Relative copy number of mitochondrial DNA
Description: Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
Study NCT01894594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)
Study NCT03052010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integrated PrEP as a bridge to ART HIV-1 prevention strategy
Description: The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
Study NCT03052010 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PrEP
Description: A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
Study NCT03052010 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ART
Description: ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
Study NCT03500822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metronome-paced tachypnea
Description: three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
Study NCT03500822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expiratory-stenosis breathing
Description: three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
Study NCT02310152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Based Treatment of Child and Adolescent Anxiety Disorders
Description: Supportive Parenting for Anxious Childhood Emotions
Study NCT02310152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study NCT01596972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dBest semi-quantitative urine pregnancy test
Description: The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
Study NCT01646450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 125mg, oral administration, three times per day.
Study NCT00042731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: Daily administration as outlined in treatment arm(s)
Study NCT00042731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Daily administration as outlined in treatment arm(s)
Study NCT00042731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Daily administration as outlined in treatment arm(s)
Study NCT01153113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT mRNA DC
Description: Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
Study NCT01153113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT mRNA DC
Description: Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
Study NCT04633941 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: Standard Care
Study NCT00991549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interdisciplinary intervention or meeting-seminars
Description: one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
Study NCT00991549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interdisciplinary intervention or meeting-seminars
Description: one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle